Published 4 days ago • loading... • Updated 3 days ago

Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working ...

On March 27, 2025, Quantum BioPharma Ltd., a biopharmaceutical company with NASDAQ ticker QNTM and FRA ticker 0K91, announced the appointment of Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor.
Quantum BioPharma focuses on treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, and is dedicated to building a portfolio of innovative assets and biotech solutions.
CEO Zeeshan Saeed stated that Terry Lynch, who has experience raising capital in mining and biotech, brings valuable communication skills and expertise to the board.
Lynch is the CEO of Power Metallic Mines Inc. , which recently closed a $50 million financing in February 2025, and is also a co-founder of Cardiol Therapeutics, a NASDAQ and TSX listed clinical-stage life sciences company researching cannabidiol for cardiovascular disease.
In connection with his appointment, Mr. Lynch was granted 50,000 stock options to acquire Class B Shares at an exercise price of C$9.90 per share, expiring on March 26, 2027, pursuant to the Company's equity incentive plan.

Insights by Ground AI

Does this summary seem wrong?

17 Articles

All

Left

Center

Right

Eagle-Tribune

+3 Reposted by 3 other sources

Center

Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working ...

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.

3 days ago

Read Full Article

The Hamilton Spectator

+4 Reposted by 4 other sources

Lean Left

Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

3 days ago·Hamilton, Canada

Read Full Article

Globe Newswire

+2 Reposted by 2 other sources

Center

Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is...

4 days ago

Read Full Article

newsbudz.com

Reposted by

Green Market Report

Quantum BioPharma pushes clinical pipeline after rebranding

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) said Friday it's made some inroads with its financials in 2024, removing its going concern designation as it looks to advance its clinical pipeline for brain disorders and alcohol-related health products. The company, which rebranded from FSD Pharma in August, posted cash... Please login to read all 377 words.

3 days ago

Read Full Article

csimarket.com

#Quantum BioPharma Fortifies Its Future: Embracing Digital Assets and Governance with Strategic Board Appointment

Quantum BioPharma Fortifies Its Future: Embracing Digital Assets and Governance with Strategic Board Appointment In a significant move that underscores its commitment to proactive financial management and innovative governance, Quantum BioPharma Ltd. (NASDAQ: QNTM) has announced the appointment of Terry Lynch to its board of directors, succeeding Dr. Sanjiv Chopra, who has opted to resign. This strategic appointment is poised to enhance the comp…

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year